Long-acting GHRH analog peptide with DAC modification
DAC:GRF
A DAC-conjugated GHRH analog providing extended GH elevation; studied in human PK trials but not FDA approved.
- Evidence:
- Limited human evidence
- Status:
- Not FDA-approved
- Reviewed:
- 2026-08-03
Also known as: DAC:GRF, Drug affinity complex CJC-1295
What is DAC:GRF?
A DAC-conjugated GHRH analog providing extended GH elevation; studied in human PK trials but not FDA approved.
This profile is educational. It organizes publicly discussed research context for DAC:GRF and related naming aliases — it is not a treatment guide.
Proposed mechanism
Albumin binding via DAC extends half-life, producing sustained GHRH receptor activation and elevated IGF-1.
Mechanism language on PepGuide describes how researchers discuss pathways. Proposed mechanisms can change as evidence evolves.
Current research notes
Human evidence grade: Limited human evidence
Preclinical evidence grade: Moderate human evidence
CJC-1295 DAC demonstrated multi-day GH elevation in healthy volunteers (Teichman 2006). Popular in research/peptide communities despite lack of approval. Concerns about non-pulsatile GH exposure. WADA prohibited.
Key uncertainties
- Safety of sustained GH elevation vs pulsatile physiology
Research areas being studied
- GH axis
- Long-acting secretagogues
Being studied for a topic is not the same as proven benefit in that topic. Prefer primary literature for study design, endpoints, and limitations.
Safety & side-effect notes
Reported or discussed adverse effects
- Injection-site reactions
- Headache
- Water retention reported
Additional risks & considerations
- Continuous GH exposure theoretical concerns
- WADA prohibited
- Unregulated products
Regulatory status
Not FDA-approved
Regulatory framing here is educational and can lag policy changes. Check official sources for current status.
Frequently asked questions
What is DAC:GRF?
A DAC-conjugated GHRH analog providing extended GH elevation; studied in human PK trials but not FDA approved.
How does DAC:GRF work (proposed mechanism)?
Albumin binding via DAC extends half-life, producing sustained GHRH receptor activation and elevated IGF-1.
What is DAC:GRF being researched for?
DAC:GRF has been discussed in research contexts including: GH axis, Long-acting secretagogues.
What does current evidence say about DAC:GRF?
Limited human evidence. CJC-1295 DAC demonstrated multi-day GH elevation in healthy volunteers (Teichman 2006). Popular in research/peptide communities despite lack of approval. Concerns about non-pulsatile GH exposure. WADA prohibited.
What safety considerations are noted for DAC:GRF?
Reported or discussed considerations include: Injection-site reactions; Headache; Water retention reported; Continuous GH exposure theoretical concerns; WADA prohibited; Unregulated products. This is educational information, not medical advice.
References & sources
- Teichman SL et al. (2006). Prolonged stimulation of GH by CJC-1295 with DAC — J Clin Endocrinol Metab. Evidence type: human.
Prefer interactive tools? Open the PepGuide library entry for DAC:GRF or ask PepGuide AI.
Educational and research information only. PepGuide does not sell or prescribe peptides, diagnose conditions, or provide personalized medical advice. Evidence summaries may include early-stage, animal, or limited human research — none of that is a substitute for primary literature or clinician guidance.